Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$118.3MCash on Hand
52.4mo Cash Runway
Follow AVXL by emailGet an email when AVXL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AVXL, unsubscribe in one click. Privacy
📣 What AVXL Says Is Next
fourth quarter · “Webcast / Conference Call Information Anavex intends to host its next webcast and conference call with its 2026 fourth quarter and full year fiscal financial results.”
Company press release, Aug 25, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Leadership Anavex appointed Terrie Kellmeyer, Ph.D., as President and CEO effective immediately, replacing her interim role, and she joined the Board as the Board shrank from six to five. Her base salary stays at $500,000. Form 8-K · SEC filing · Press release
Nov 2, 2026 ·
Leadership Three directors, Jiong Ma (Chair), Gautam Patel and Adrian Senderowicz, resigned effective October 28, 2026, citing views on strategy not aligned with the Board and management. On November 1, 2026 the Board reconstituted its committees, with Claus van der Velden as Audit Chair. Form 8-K · SEC filing
Oct 20, 2026 ·
Clinical trial Anavex said clinical conduct of its ADME study (8 healthy volunteers) and DDI study (65 participants) for blarcamesine is complete, with no serious adverse events reported preliminarily; full analysis is ongoing. An FDA meeting on adding pediatric participants to the Rett syndrome Phase 3 is set for November. Form 8-K · SEC filing · Press release
Oct 15, 2026 ·
Regulatory FDA cleared Anavex's IND for blarcamesine in Fragile X syndrome, allowing a planned Phase 2a study of about 60 adult males. Blarcamesine has Orphan Drug Designation for this indication, and no FDA-approved treatment exists. Form 8-K · SEC filing · Press release
Sep 28, 2026 ·
Leadership A proxy contest at the September 24, 2026 annual meeting left only three incumbent directors, below a board majority, which triggered a change in control. All outstanding unvested equity awards, including the CFO's, vested in full. Form 8-K · SEC filing
Sep 9, 2026 ·
Regulatory Anavex is prioritizing its ANAVEX 2-73 (blarcamesine) pipeline in early Alzheimer's disease, Rett syndrome and Fragile X syndrome, and is moving forward with a Phase 3 trial in adult Rett syndrome patients. The FDA has granted the company's request for a meeting on including pediatric patients in that Phase 3 trial. Form 8-K · SEC filing
Aug 28, 2026 ·
Amended annual report for the period ended Sep 30, 2025 Form 10-K/A · SEC filing
Aug 28, 2026 ·
Amended quarterly report for the period ended Dec 31, 2025 Form 10-Q/A · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2025 · Phase 2 · Active Trial · A Study of ANAVEX3-71 in Adults With Schizophrenia Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AVXL holds $118.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.8M/quarter from operations,
an estimated runway of 52.4 months at that rate (BioRadar estimate, not company guidance).
Share count 92,696,842 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AVXL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVXL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.